Performance in physical tests can help manage treatment for metastatic lung cancer
A study of patients with metastatic lung cancer by researchers based in Brazil and the United States has found that their ...
There may be gas in your home causing lung cancer. Here's what to do about it
Municipalities in Newfoundland and Labrador are taking action against radon, an invisible radioactive gas that causes lung ...
Hosted on MSN7mon
The lung cancer blood test from eligibility to where it is available, explained
A new blood test which could help thousands of people receive ... which accounts for at least 80 per cent of lung cancer cases – that can be taken at home by patients, Professor Popat said: “These ...
Lung cancer spit test fast-tracks a San Antonio biotech company for growth
More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...
Indiatimes5d
This 5-second finger test can help detect early lung cancer signs
A 5-second finger test may help detect early lung cancer signs. By analyzing finger patterns, one can identify finger clubbing, an indicator in over 35% of non-small cell lung cancer cases.
Business Wire14d
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath ® Lung Test
Affinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at ...
360dx14d
BioAffinity Technologies' Lung Cancer Test Added to Federal Supply Schedule
CyPath Lung is a laboratory-developed assay that uses self-collected sputum samples treated with a fluorescent compound that preferentially binds to cancer cells and cancer-related cells, San ...
Morningstar7d
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
“Our CyPath® Lung noninvasive test for the early detection of lung cancer is a novel test that uses sputum, a unique sample type that is not typically used in clinical flow cytometry assays ...
Business Wire1mon
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and ...
SAN ANTONIO, Texas--(BUSINESS WIRE)--A new economic study found that adding CyPath® Lung, bioAffinity Technologies’ noninvasive test for detection of early-stage lung cancer, to the standard of ...
360dx2d
Cizzle Biotechnology Inks Licensing Deal to Bring Lung Cancer Blood Test to Market in 2025
UK-based Cizzle Biotechnology signed the licensing agreement with its US-based partner, Cizzle Bio, for the commercialization of early cancer detection tests.
Yahoo Finance7d
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
bioAffinity VP served on expert panel that published new guidance SAN ANTONIO, October 16, 2024--(BUSINESS WIRE)--bioAffinity Technologies’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics ...
Morningstar14d
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that CyPath® Lung ...